London, 22 February 2018 Sinclair Pharma plc (AIM:SPH.L) ('Sinclair' or the 'Group'), the international aesthetics company, is pleased to announce a $5 million investment in the Group via the issue of a $5.0 million convertible loan to EW Healthcare Partners ('EW'). The proceeds of the investment will be used to finance the one-off payment and acquisition of inventory arising from termination of the distribution agreement between Sinclair and ThermiGen LLC as set out in the announcement issued earlier today. EW is a specialist investor focussed on raqpidly growing healthcare companies and holds several investments in medical aesthetics. The total value of the convertible will be $5.0 million and interest will accrue at 8%, compounded annually, and if not converted into ordinary shares, will mature no earlier than 1 September 2020. The convertible loan will be secured by way of a second ranking charge over Sinclair's assets. Conversion into ordinary shares in Sinclair can occur at any time from three months after the date of issue and in the event that the loan is converted into ordinary shares EW have agreed to a lock-up of six months subject to certain exemptions. The conversion price is 28.0p, representing a 27% premium to Sinclair's closing middle market price on 21 February 2018. Assuming the entire $5 million loan is converted into new ordinary shares in Sinclair EW would be issued a total of 12,800,000 ordinary shares being 2.5% of the Company's current issued ordinary share capital of 503,768,952 ordinary shares. There is an adjustment mechanism within the loan agreement such that in the event that Sinclair issues additional ordinary shares prior to conversion of the loan, EW will still receive a fixed 2.5% of the Company's then issued share capital at the time of conversion. Chris Spooner, CEO of Sinclair, commented: 'I am delighted that we have attracted investment from EW Healthcare Partners, a well respected investment firm with many years of experience and success investing in the healthcare industry. We look forward to working closely with the EW team and leveraging their experience and relationships within the US aesthetics industry and more widely.' Ron Eastman, managing director of EW, commented: 'We have been impressed with the significant growth that Sinclair is experiencing and we look forward to leveraging our experience of successfully investing in the aesthetics market to help Sinclair enhance its global potential.' For more information click here to download PDF.
Plastic surgery company Sinclair Pharma has received a $5m convertible loan from EW Healthcare Partners, its latest investment in the cosmetic procedures sector. Sinclair will use the funds to settle the early termination of a deal with ThermiGen to distribute face-lift products and procedures.